ClinicalTrials.gg
CompletedNCT07177209EFFECT-1LATUpdated Nov 6, 2026

Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population

An observational study in Ulcerative Colitis, sponsored by Pfizer. Completed at 1 site in United Kingdom. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Pfizer · Observational

How we know

Updated Nov 6, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
4,000
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Colitis, Ulcerative by Pfizer — 2 open to participants now, 7 under way, 2 of them phase 3. Colitis, Ulcerative · Pfizer.

Enrollment
Largest of 16
4,000 · median 276
Started
2026
with 2 others
Observational
16 of 42
none open now
Registered
40th of 42
by date

Among the 42 studies in Colitis, Ulcerative by Pfizer, this one has the largest enrollment of the 16 observational ones that give a count, is one of 3 that started in 2026, is one of 16 observational ones, and was the 40th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

2 of the 42 studies in Colitis, Ulcerative by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Colitis, Ulcerative by Pfizer, or all of them as a file.
02

Study summary

Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population

Read the detailed description

Exploring the long-term outcomes of uncontrolled inflammation, and how does early switching to advanced treatments affect disease outcomes and inflammation control in patients with poorly controlled ulcerative colitis.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The Lothian IBD registry (LIBDR) was compiled through a capture-recapture methodology, describes the observed prevalence of IBD in Lothian between 2008 and 2018, and has been maintained as a prospective registry since 1 August 2018 and thus the study period is up to 1st August 2025 (2008 - 2025). The study size is expected to be a defined population of approximately 4000 UC patients, with more than 600 having commenced an advanced therapy. The study period will be from 2008 - 2025.

Eligibility criteria

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

  1. Patient enrolled in IBD registry from 2009
  2. >18 years at time of diagnosis.
  3. Diagnosis of Ulcerative Colitis.
  4. Patient data entered during the study period.
  5. Minimum duration of data post UC diagnosis (Cohort A: 6 months, Cohort B-D 6 months)
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
4,000 participants (actual)
Patient registry
No

Groups and cohorts

  • Cohort A

    Patients within the Lothian IBD registry, approximately 4000 patients, of which 3200 are on conventional therapy.

    Drug: Non-Interventional Study

  • Cohort B

    Patients with uncontrolled inflammation defined as two or more episodes of raised CRP or faecal calprotectin recording 6-24 months post UC diagnosis.

    Drug: Non-Interventional Study

  • Cohort C

    Patients with steroid dependent controlled inflammation defined as normal CRP and faecal calprotectin but the requirement of a dose of steroids between 6-24 months.

    Drug: Non-Interventional Study

  • Cohort D

    Patients with controlled inflammation defined as the absence of steroid requirement or normal CRP or faecal calprotectin 6-24 months post UC diagnosis

    Drug: Non-Interventional Study

Interventions

  • DrugEtrasimodStudies of EtrasimodEtrasimod pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    As provided in real world practice

    Also known as: etrasimod, ozanimod, upadicitinib, filgotinib, tofacitinib, vedolizumab, guselkumab, ustekinumab, risankizumab, adalimumab, infliximab, golimumab

06

What researchers measure

Primary outcomes

  1. Proportion of patients that achieve early control of inflammation on conventional therapeutics within 6-24 months of UC diagnosis.

    Proportion of patients that achieve early control of inflammation on conventional therapeutics within 6-24 months of UC diagnosis in the Lothian inflammatory bowel disease registry (LIBDR).

    Time frame: 6-24 months from UC diagnosis.

  2. Difference in proportion of patients with inadequate control of inflammation (defined as two or more episodes of raised CRP or faecal calprotectin) treated with conventional therapeutics versus treatment escalation 24 months post UC diagnosis.

    Explore the differences in long term outcomes for patients with uncontrolled inflammation, treated with prolonged conventional therapeutics versus treatment escalation up to 24 months for patients with inadequate control of inflammation in the Lothian inflammatory bowel disease registry (LIBDR).

    Time frame: 24 months

Secondary outcomes

  1. Characterise patient demography at the time of diagnosis and associated co-morbidities and extra-intestinal manifestations of interest.

    Characterise patient demography at the time of UC diagnosis and associated co-morbidities and extra-intestinal manifestations of interest in the Lothian inflammatory bowel disease registry (LIBDR).

    Time frame: Baseline demography.

  2. Map treatment use from conventional therapies to advanced therapies from time of UC diagnosis.

    Map treatment use from from conventional therapies to advanced therapies from time of UC diagnosis in the Lothian inflammatory bowel disease registry (LIBDR).

    Time frame: Study period is up to 1st August 2025 (2008 - 2025).

  3. Change from Baseline in Faecal Calprotectin (Fcal).

    Generate Faecal Calprotectin (Fcal) profile and longitudinal inflammatory response models for patients on conventional therapy in the Lothian inflammatory bowel disease registry (LIBDR).

    Time frame: Study period is up to 1st August 2025 (2008 - 2025).

  4. Change from Baseline in C-Reactive Protein (CRP).

    Generate C-Reactive Protein (CRP) profile and longitudinal inflammatory response models for patients on conventional therapy in the Lothian inflammatory bowel disease registry (LIBDR).

    Time frame: Study period is up to 1st August 2025 (2008 - 2025).

  5. Proportion of patients with colectomies from baseline.

    Assess colectomy rates of patients in the Lothian inflammatory bowel disease registry (LIBDR) with a relevant UC diagnosis.

    Time frame: Study period is up to 1st August 2025 (2008 - 2025).

  6. Proportion of patients with hospitalisations from baseline.

    Assess hospitalisation rates in the Lothian inflammatory bowel disease registry (LIBDR) with a relevant UC diagnosis.

    Time frame: Study period is up to 1st August 2025 (2008 - 2025).

  7. Proportion of patients with advanced therapy (AT) requirements with relevant UC diagnosis.

    Assess advanced therapy (AT) requirements in the Lothian inflammatory bowel disease registry (LIBDR).

    Time frame: Study period is up to 1st August 2025 (2008 - 2025).

  8. Correlate duration of uncontrolled inflammation within first 6-24 months of treatment to long term outcomes as provided in real world evidence practice.

    Duration of uncontrolled inflammation in the Lothian inflammatory bowel disease registry (LIBDR).

    Time frame: Study period is up to 1st August 2025 (2008 - 2025).

  9. Describe the effects of conventional treatment to AT's (etrasimod and tofacitinib) by change from baseline in steroid utilisation.

    Effects of conventional treatment to advanced therapies (AT's) in steroid utilisation in the Lothian inflammatory bowel disease registry (LIBDR).

    Time frame: Study period is up to 1st August 2025 (2008 - 2025).

  10. Change from baseline in control of inflammation (CRP or faecal calprotectin) in patients that are moved from conventional treatments to advanced treatments with a UC diagnosis.

    Describe the effects of changing from conventional treatment to advanced treatments (etrasimod and tofacitinib) in control of inflammation (CRP or faecal calprotectin) in the Lothian inflammatory bowel disease registry (LIBDR).

    Time frame: From baseline, study period is up to 1st August 2025 (2008 - 2025).

07

Study locations

1 site
  • Pfizer
    Tadworth, KT207NS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2026 to primary completion in Oct 2026, 6 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Jul 2026 → Oct 2026 and completion Jul 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2025
First posted
Sep 16, 2025
StartActual
Apr 1, 2026
Primary completionActual
Oct 30, 2026was Jul 2026
CompletionActual
Oct 30, 2026was Jul 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 6, 2026
Primary completion
Jul 31, 2026→Oct 30, 2026
Oct 15, 2026
Study completion
Jul 31, 2026→Oct 30, 2026
Oct 15, 2026
Show all 2 updates
  1. Nov 6, 2026
    Active, not recruiting→Completed
    + 2 other changes: verification date and date precision
  2. Oct 15, 2026
    Primary completion Jul 31, 2026→Oct 30, 2026
    Study completion Jul 31, 2026→Oct 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07177209
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 16, 2025
Start date
Apr 1, 2026
Primary completion
Oct 30, 2026
Completion
Oct 30, 2026
Last update
Nov 6, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion